Euronext

ING to file 2022 Annual Report on Form 20-F

Retrieved on: 
Friday, March 10, 2023
Lung compliance, Legislation, Failure, FTSE Russell, Life, Sustainability, AA, ING Group, Turnaround ADR, Climate change, Biophysical environment, MSCI, Annual report, Internet, Risk, ESG, Sustainalytics, United, S&P Global Ratings, Social, Morning Star, COVID-19, European, ING, FATCA, Rare-earth element, Cryptocurrency, Euronext, EU

ING is a global financial institution with a strong European base, offering banking services through its operating company ING Bank.

Key Points: 
  • ING is a global financial institution with a strong European base, offering banking services through its operating company ING Bank.
  • ING Bank’s more than 58,000 employees off er retail and wholesale banking services to customers in over 40 countries.
  • ING Group shares are listed on the exchanges of Amsterdam (INGA NA, INGA.AS), Brussels and on the New York Stock Exchange (ADRs: ING US, ING.N).
  • As of August 2022, Sustainalytics considers ING’s management of ESG material risk to be ‘strong’, and in June 2022 ING received an ESG rating of 'strong' from S&P Global Ratings.

ING to nominate Alexandra Reich as member of the Supervisory Board, releases proxy materials for 2023 AGM

Retrieved on: 
Friday, March 10, 2023
Lung compliance, Legislation, Failure, FTSE Russell, Life, Sustainability, AA, ING Group, Turnaround ADR, Climate change, Biophysical environment, MSCI, Annual report, Internet, Risk, ESG, Sustainalytics, United, S&P Global Ratings, Social, Morning Star, COVID-19, European, ING, FATCA, Rare-earth element, Cryptocurrency, Euronext, EU

ING is a global financial institution with a strong European base, offering banking services through its operating company ING Bank.

Key Points: 
  • ING is a global financial institution with a strong European base, offering banking services through its operating company ING Bank.
  • The purpose of ING Bank is empowering people to stay a step ahead in life and in business.
  • ING Bank’s more than 58,000 employees off er retail and wholesale banking services to customers in over 40 countries.
  • ING Group shares are listed on the exchanges of Amsterdam (INGA NA, INGA.AS), Brussels and on the New York Stock Exchange (ADRs: ING US, ING.N).

ING publishes 2022 Annual Report

Retrieved on: 
Thursday, March 9, 2023
Lung compliance, Legislation, Failure, FTSE Russell, Life, Sustainability, AA, ING Group, Turnaround ADR, Climate change, Biophysical environment, MSCI, Annual report, Internet, Risk, ESG, Sustainalytics, United, S&P Global Ratings, Social, Morning Star, COVID-19, European, ING, FATCA, Rare-earth element, Cryptocurrency, Euronext, EU

ING is a global financial institution with a strong European base, offering banking services through its operating company ING Bank.

Key Points: 
  • ING is a global financial institution with a strong European base, offering banking services through its operating company ING Bank.
  • ING Bank’s more than 58,000 employees off er retail and wholesale banking services to customers in over 40 countries.
  • ING Group shares are listed on the exchanges of Amsterdam (INGA NA, INGA.AS), Brussels and on the New York Stock Exchange (ADRs: ING US, ING.N).
  • As of August 2022, Sustainalytics considers ING’s management of ESG material risk to be ‘strong’, and in June 2022 ING received an ESG rating of 'strong' from S&P Global Ratings.

Nyxoah to Release Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023

Retrieved on: 
Wednesday, March 8, 2023
CET, Conference, Mont-Saint-Guibert, Euronext, OSA, Obstructive sleep apnea

Nyxoah to Release Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023

Key Points: 
  • Nyxoah to Release Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
    Mont-Saint-Guibert, Belgium – March 8, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the fourth quarter and full year 2022 on Wednesday, March 22, 2023, after market close.
  • Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.
  • Investors interested in listening to the conference call may do so by registering for a unique personal PIN at the following link: Conference Registration (vevent.com) .
  • A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.nyxoah.com/events .

SHAPING THE FUTURE FOR TECHNICOLOR CREATIVE STUDIOS FOLLOWING AGREEMENT ON ITS REFINANCING

Retrieved on: 
Wednesday, March 8, 2023
AMF, Convertible, Commercial Court, Sale, Commercial Court (Victoria), Technicolor Creative Studios, Prospectus, Fiducial inference, Original issue discount, Lien, AFEP, Mass meeting, Euronext Paris, Commercial, Documentation, Angelo Gordon, Creditor, Annual general meeting, Vantiva, Credit, New Money, Date, Agreement in principle, Film industry, Bank, Security (finance), Cryptocurrency, Lease, Self storage, Euronext, TCS, Principle

Technicolor Creative Studios reaches an agreement in principle on a €170m new money injection, including recapitalization

Key Points: 
  • Technicolor Creative Studios reaches an agreement in principle on a €170m new money injection, including recapitalization
    Paris (France), March 8, 2023 – Technicolor Creative Studios is pleased to announce an agreement in principle that provides a framework for rebound of the Company to the benefit of its studios, talents, customers and suppliers.
  • The Company has reached an agreement in principle on a new financing structure which includes a c.€170 million new money injection.
  • This would enable Technicolor Creative Studios to address its liquidity needs from Q2 2023 and allows operating cash flow to be focused on operational needs.
  • Anne Bouverot, Chairperson, and Caroline Parot, CEO: “This new favorable framework reaffirms the strong commitment of all our stakeholders, in particular our shareholders and lenders, and demonstrates their renewed confidence in the long-term prospects of Technicolor Creative Studios.

Nyxoah to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Retrieved on: 
Tuesday, March 7, 2023
CET, Conference, Mont-Saint-Guibert, Euronext, Obstructive sleep apnea, OSA

Mont-Saint-Guibert, Belgium – March 7, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Oppenheimer 33rd Annual Healthcare Conference, which takes place March 13-15, 2023, virtually.

Key Points: 
  • Mont-Saint-Guibert, Belgium – March 7, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Oppenheimer 33rd Annual Healthcare Conference, which takes place March 13-15, 2023, virtually.
  • Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a corporate update on Tuesday, March 14, 2023, at 11:20am ET.
  • A webcast of the presentation will be available in the Events section of Nyxoah’s Investor Relations website.
  • Nyxoah’s Investor Presentation can be accessed on the Shareholder Information section of the Company’s Investor Relations page.

DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old

Retrieved on: 
Tuesday, March 7, 2023
DBV, Element, Children's Hospital Colorado, Month, FDA, Skin, Trial of the century, Peanut allergy, Research, Principal investigator, Immune system, Clinical trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, DBV Technologies, BLA, Allergy, Food, CRD, Pharmaceutical industry, Euronext, MD

The VITESSE trial will use the modified Viaskin Peanut 250 μg patch and enroll 600 subjects, randomized 2:1 active versus placebo.

Key Points: 
  • The VITESSE trial will use the modified Viaskin Peanut 250 μg patch and enroll 600 subjects, randomized 2:1 active versus placebo.
  • The study will involve approximately 80 trial sites across the United States, Canada, Australia, and Europe.
  • The primary efficacy endpoint of the study is the percentage of treatment responders in the active versus placebo arms at Month 12.
  • Secondary efficacy endpoints include changes in cumulative reactive dose (CRD), eliciting dose (ED) and severity of allergic reaction at Month 12 food challenge.

ING completes share repurchase for employee compensation

Retrieved on: 
Tuesday, March 7, 2023
MSCI, AA, United, FATCA, Biophysical environment, Lung compliance, ING, ING Group, COVID-19, ESG, FTSE Russell, Sustainability, Internet, Climate change, S&P Global Ratings, Morning Star, Turnaround ADR, Life, European, Annual report, Sustainalytics, Failure, Risk, Social, Legislation, Rare-earth element, Cryptocurrency, Euronext, EU

ING is a global financial institution with a strong European base, offering banking services through its operating company ING Bank.

Key Points: 
  • ING is a global financial institution with a strong European base, offering banking services through its operating company ING Bank.
  • The purpose of ING Bank is empowering people to stay a step ahead in life and in business.
  • ING Bank’s more than 58,000 employees off er retail and wholesale banking services to customers in over 40 countries.
  • ING Group shares are listed on the exchanges of Amsterdam (INGA NA, INGA.AS), Brussels and on the New York Stock Exchange (ADRs: ING US, ING.N).

STMicroelectronics Announces Changes to Euronext Trading Symbols

Retrieved on: 
Monday, March 6, 2023
MTA, Electronics, STM, Environment, STMicroelectronics, NYSE, Borsa Italiana, Euronext Paris, Security (finance), Euronext

Geneva, March 6, 2023 - STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, announces that effective Monday, March 13, 2023, prior to the stock exchanges market openings, the trading symbols of STMicroelectronics common shares listed on Euronext will change.

Key Points: 
  • Geneva, March 6, 2023 - STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, announces that effective Monday, March 13, 2023, prior to the stock exchanges market openings, the trading symbols of STMicroelectronics common shares listed on Euronext will change.
  • For the Euronext Paris listing in Paris, it will become ‘STMPA’.
  • Given the migration of the Borsa Italiana markets onto the Euronext trading platform, it was necessary to create two separate trading symbols, as now the two order books will be traded in the same environment.
  • The ‘STM’ trading symbol on the New York Stock Exchange remains unchanged.

Nyxoah Announces Achievement of Key Clinical and Regulatory Milestones

Retrieved on: 
Monday, March 6, 2023
DREAM, Euronext, Oxygen, Diagnosis, OSA, Observational study, Mont-Saint-Guibert, CET, AHI, Obstructive sleep apnea, IDE, Patient, PMA, Apnea–hypopnea index, ODI, Notre Dame of Genio Edcor Inc., CCC, Medical device, Pharmaceutical industry

The DREAM study is a pivotal, investigational device exemption (IDE) trial designed to support the marketing authorization of the Genio® hypoglossal nerve stimulation system (HGNS) in the United States.

Key Points: 
  • The DREAM study is a pivotal, investigational device exemption (IDE) trial designed to support the marketing authorization of the Genio® hypoglossal nerve stimulation system (HGNS) in the United States.
  • In the ACCCESS trial, Nyxoah will implant 106 complete concentric collapse (CCC) patients with co-primary efficacy endpoints of Apnea-Hypopnea Index (AHI) responder rate, per the Sher criteria, and Oxygen Desaturation Index (ODI) responder rate, both assessed at 12 months post-implant.
  • “The achievement of these key clinical and regulatory milestones brings us closer to offering our patient centric Genio solution to all OSA patients in the U.S.
  • The DREAM and ACCCESS studies demonstrate Nyxoah’s mission of providing Genio to patients regardless of CCC status and without the requirement for a CCC diagnosis,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer.